Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial.

@article{Schweighardt2015ImmunogenicityOE,
  title={Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial.},
  author={Becky Schweighardt and Troy Tompkins and Kelly Shukkwan Lau and Lynne Jesaitis and Yulan Qi and Donald G. Musson and Pamela J. Farmer and Christine A. Haller and Adam J. Shaywitz and Ke Yang and Charles O'Neill},
  journal={Clinical therapeutics},
  year={2015},
  volume={37 5},
  pages={1012-1021.e6}
}
PURPOSE Morquio A syndrome (mucopolysaccharidosis IVA [MPS IVA]) is a lysosomal storage disorder caused by deficiency of the enzyme N-acetylgalactosamine-6-sulfatase, which is required to degrade the glycosaminoglycan keratan sulfate. Morquio A is associated with extensive morbidity and early mortality. Elosulfase alfa is an enzyme replacement therapy that provides a treatment option for patients with Morquio A. We examined the immunogenicity profile of elosulfase alfa, assessing any… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 7 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Similar Papers

Loading similar papers…